...And Well-Informed, Responsible Opposition

I was appalled at Michael J. Moravcsik’s commentary on the SSC (THE SCIENTIST, June 1, 1987, p. 11). I welcome the expression of differences when they are based on well-informed points of view. The first of his four points might generously be interpreted in that way. The other three are glaringly factually incorrect and, therefore, quite irresponsible. First, elementary particle physics is today’s “physics of the very small.” The previous two generations of that most

Written byEdwin Goldwasser
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

I was appalled at Michael J. Moravcsik’s commentary on the SSC (THE SCIENTIST, June 1, 1987, p. 11). I welcome the expression of differences when they are based on well-informed points of view. The first of his four points might generously be interpreted in that way. The other three are glaringly factually incorrect and, therefore, quite irresponsible.

First, elementary particle physics is today’s “physics of the very small.” The previous two generations of that most “reductionist” (to use Bob Schrieffer’s word) field of fundamental research have been atomic physics and nuclear physics. Surely those fields have no apologies to make for their contributions to our science, our culture, our technology, or our industry. So, high-energy physics is not a field that “suffers” from Big Science syndrome. Rather, it is a field that has arrived at a point where it knows a set of questions that are important to answer and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies